Yu S, Li H, Lu H, Huang Z, et al. Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies. Int J Cancer 2025 Nov 6. doi: 10.1002/ijc.70224.
PMID: 41195833